Impact of timing of antiretroviral treatment and birth weight on mother-to-child human immunodeficiency virus transmission: findings from an 18-month prospective cohort of a nationally representative sample of mother–infant pairs during the transition from Option A to Option B+ in Zimbabwe

Clinical Infectious Diseases

Volumn 66, Issue 4, 2018, Pages 576-585

  Dinh, Thu Ha ^a   Mushavi, Angela ^b   Shiraishi, Ray W ^a   Barr, Beth Tippett ^a   Balachandra, Shirish ^a   Shambira, Gerald ^c   Nyakura, Justice ^c   Zinyowera, Sekesai ^d   Tshimanga, Mufuta ^c   Mugurungi, Owen ^b   Kilmarx, Peter H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Ministry of Health and Child Care of Zimbabwe

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d MINISTRY OF HEALTH AND CHILD CARE   (Zimbabwe)

Author keywords

ART initiation.; Birth weight; Mother to child HIV transmission; Zimbabwe

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; BIRTH WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MOTHER CHILD RELATION; OBSERVATIONAL STUDY; OBSTETRIC DELIVERY; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME TO TREATMENT; VIRUS TRANSMISSION; ZIMBABWE; ADOLESCENT; BREAST FEEDING; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; MOTHER; NEWBORN; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; TIME FACTOR; VERTICAL TRANSMISSION; VIROLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BIRTH WEIGHT; BREAST FEEDING; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; TIME FACTORS; ZIDOVUDINE; ZIMBABWE;

EID: 85045946368     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix820     Document Type: Article

References (39)

1. Joint United Nations Programme on HIV/AIDS. How AIDS changed everything—MDG6: 15 years, 15 lessons of hope from the AIDS response. Geneva, Switzerland: UNAIDS, 2015.
2. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, 2010. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2010.
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2015. Geneva, Switzerland: WHO, 2013.
4. Joint United Nations Programme on HIV/AIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva, Switzerland: UNAIDS, 2011.
5. World Health Organization. Elimination of mother-to-child transmission (EMTCT) of HIV and syphilis. Global guidance on criteria and processes for validation. Geneva, Switzerland: WHO, 2014.
6. Wiegert K, Dinh TH, Mushavi A, Mugurungi O, Kilmarx PH. Integration of prevention of mother-to-child transmission of HIV (PMTCT) postpartum services with other HIV care and treatment services within the maternal and child health setting in Zimbabwe, 2012. PLoS One 2014; 9:e98236.
7. World Health Organization. Measuring the impact of national PMTCT programmes: towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. A short guide on methods. Geneva, Switzerland: WHO, 2012.
8. World Health Organization. WHO recommendations on the diagnosis of HIV infection in infants and children. Geneva, Switzerland: WHO, 2010.
9. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata Journal 2004:9.
10. Heeringa S, West BT, Berglund PA. Applied survey data analysis. Boca Raton, FL: Chapman & Hall/CRC, 2010.
11. McCoy SI, Fahey C, Buzdugan R, et al. Targeting elimination of mother-to-child HIV transmission efforts using geospatial analysis of mother-to-child HIV transmission in Zimbabwe. AIDS 2016; 30:1829–37.
12. Buzdugan R, Kang Dufour MS, McCoy SI, et al. Option A improved HIV-free infant survival and mother to child HIV transmission at 9–18 months in Zimbabwe. AIDS 2016; 30:1655–62.
13. Goga AE, Jackson D, Lombard C, et al. Highest risk of mother to child transmission of HIV or death in the first 6 months postpartum: results from 18 month follow-up of an HIV-exposed national cohort, South Africa. 2016. Available at: http://programme.aids2016.org/Search/Search?search=Goga. Accessed 30 November 2016.
14. Goga AE, Dinh TH, Jackson DJ, et al.; South Africa PMTCT Evaluation (SAPMCTE) Team. Population-level effectiveness of PMTCT Option A on early mother-to-child (MTCT) transmission of HIV in South Africa: implications for eliminating MTCT. J Glob Health 2016; 6:020405.
15. Ngoma MS, Misir A, Mutale W, et al. Efficacy of WHO recommendation for continued breastfeeding and maternal cART for prevention of perinatal and postnatal HIV transmission in Zambia. J Int AIDS Soc 2015; 18:19352.
16. Chasela CS, Hudgens MG, Jamieson DJ, et al.; BAN Study Group. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271–81.
17. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119–29.
18. SWEN Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300–13.
19. Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2010; 54:35–41.
20. Mandelbrot L, Tubiana R, Le Chenadec J, et al.; ANRS-EPF Study Group. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis 2015; 61:1715–25.
21. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 2014; 28:1049–57.
22. Njom Nlend AE, Nga Motazé A, Moyo Tetang S, Zeudja C, Ngantcha M, Tejiokem M. Preterm birth and low birth weight after in utero exposure to antiretrovirals initiated during pregnancy in Yaoundé, Cameroon. PLoS One 2016; 11:e0150565.
23. Tookey PA, Thorne C, van Wyk J, Norton M. Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland. BMC Infect Dis 2016; 16:65.
24. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12:F241–7.
25. European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913–20.
26. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380–7.
27. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337–9.
28. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis 2007; 196:558–61.
29. Ravizza M, Martinelli P, Bucceri A, et al.; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195:913–4; author reply 916–7.
30. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019–26.
31. Grosch-Woerner I, Puch K, Maier RF, et al.; Multicenter Interdisciplinary Study Group Germany/Austria. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9:6–13.
32. Rudin C, Spaenhauer A, Keiser O, et al.; Swiss HIV Cohort Study; Swiss Mother and Child HIV Cohort Study. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med 2011; 12:228–35.
33. Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 2012; 26:37–43.
34. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348–60.
35. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380–7.
36. Singh VV, Chauhan SK, Rai R, Kumar A, Singh SM, Rai G. Decreased pattern recognition receptor signaling, interferon-signature, and bactericidal/permeability-increasing protein gene expression in cord blood of term low birth weight human newborns. PLoS One 2013; 8:e62845.
37. Singh VV, Chauhan SK, Rai R, Kumar A, Rai G. Decreased toll-like receptor-4/myeloid differentiation factor 88 response leads to defective interleukin-1β production in term low birth weight newborns. Pediatr Infect Dis J 2014; 33:1270–6.
38. Arboleya S, Sánchez B, Solís G, et al. Impact of prematurity and perinatal antibiotics on the developing intestinal microbiota: a functional inference study. Int J Mol Sci 2016; 17:649.
39. Groer MW, Luciano AA, Dishaw LJ, Ashmeade TL, Miller E, Gilbert JA. Development of the preterm infant gut microbiome: a research priority. Microbiome 2014; 2:38.